Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1401436-95-0
2. Zandelisib [inn]
3. Zandelisib [usan]
4. Pwt143
5. Acc-524
6. Pwt-143
7. Pw-143
8. 8z28m5sx0x
9. 4-[2-(difluoromethyl)benzimidazol-1-yl]-n-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine
10. 1,3,5-triazin-2-amine, 4-(2-(difluoromethyl)-1h-benzimidazol-1-yl)-n-(1,1-dimethyl-2-(2-(1-methyl-4-piperidinyl)phenyl)ethyl)-6-(4-morpholinyl)-
11. 1,3,5-triazin-2-amine, 4-[2-(difluoromethyl)-1h-benzimidazol-1-yl]-n-[1,1-dimethyl-2-[2-(1-methyl-4-piperidinyl)phenyl]ethyl]-6-(4-morpholinyl)-
12. 4-(2-(difluoromethyl)benzimidazol-1-yl)-n-(1,1-dimethyl-2-(2-(1-methyl-4-piperidyl)phenyl)ethyl)-6-morpholino-1,3,5-triazin-2-amine
13. Zandelisib [jan]
14. Unii-8z28m5sx0x
15. Zandelisib [who-dd]
16. Chembl4650214
17. Schembl12936730
18. Gtpl10627
19. Ex-a5471
20. Me-401; Pwt-143
21. Who 11202
22. Zinc148868634
23. At32468
24. Ac-35708
25. Example 51 [wo2012135160a1]
26. Hy-109198
27. Cs-0119144
28. A35 [wo2012135160a1]
| Molecular Weight | 576.7 g/mol |
|---|---|
| Molecular Formula | C31H38F2N8O |
| XLogP3 | 5.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 8 |
| Exact Mass | 576.31366419 g/mol |
| Monoisotopic Mass | 576.31366419 g/mol |
| Topological Polar Surface Area | 84.2 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 855 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Zandelisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zandelisib, including repackagers and relabelers. The FDA regulates Zandelisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zandelisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Zandelisib supplier is an individual or a company that provides Zandelisib active pharmaceutical ingredient (API) or Zandelisib finished formulations upon request. The Zandelisib suppliers may include Zandelisib API manufacturers, exporters, distributors and traders.
Zandelisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zandelisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zandelisib GMP manufacturer or Zandelisib GMP API supplier for your needs.
A Zandelisib CoA (Certificate of Analysis) is a formal document that attests to Zandelisib's compliance with Zandelisib specifications and serves as a tool for batch-level quality control.
Zandelisib CoA mostly includes findings from lab analyses of a specific batch. For each Zandelisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zandelisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Zandelisib EP), Zandelisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zandelisib USP).
LOOKING FOR A SUPPLIER?
